195 related articles for article (PubMed ID: 9143353)
1. Potency comparison of peptidomimetic inhibitors against HIV-1 and HIV-2 proteinases: design of equipotent lead compounds.
Weber J; Majer P; Litera J; Urban J; Soucek M; Vondrásek J; Konvalinka J; Novek P; Sedlácek J; Strop P; Kräusslich HG; Pichová I
Arch Biochem Biophys; 1997 May; 341(1):62-9. PubMed ID: 9143353
[TBL] [Abstract][Full Text] [Related]
2. Peptide inhibitors of HIV-1 and HIV-2 proteases: a comparative study.
Pichová I; Weber J; Litera J; Konvalinka J; Vondrásek J; Soucek M; Strop P; Majer P; Heuser AM; Kraeusslich HG
Leukemia; 1997 Apr; 11 Suppl 3():120-2. PubMed ID: 9209317
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo.
Lee T; Laco GS; Torbett BE; Fox HS; Lerner DL; Elder JH; Wong CH
Proc Natl Acad Sci U S A; 1998 Feb; 95(3):939-44. PubMed ID: 9448264
[TBL] [Abstract][Full Text] [Related]
4. Rational design, synthesis, and crystallographic analysis of a hydroxyethylene-based HIV-1 protease inhibitor containing a heterocyclic P1'--P2' amide bond isostere.
Thompson SK; Murthy KH; Zhao B; Winborne E; Green DW; Fisher SM; DesJarlais RL; Tomaszek TA; Meek TD; Gleason JG
J Med Chem; 1994 Sep; 37(19):3100-7. PubMed ID: 7932533
[TBL] [Abstract][Full Text] [Related]
5. Development of pseudopeptide inhibitors of HIV-1 aspartic protease: analysis and tuning of the subsite specificity.
Tossi A; Antcheva N; Romeo D; Miertus S
Pept Res; 1995; 8(6):328-34. PubMed ID: 8838416
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of inhibition of the retroviral protease by a Rous sarcoma virus peptide substrate representing the cleavage site between the gag p2 and p10 proteins.
Cameron CE; Grinde B; Jentoft J; Leis J; Weber IT; Copeland TD; Wlodawer A
J Biol Chem; 1992 Nov; 267(33):23735-41. PubMed ID: 1331099
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA.
Sakurai M; Higashida S; Sugano M; Komai T; Yagi R; Ozawa Y; Handa H; Nishigaki T; Yabe Y
Bioorg Med Chem; 1994 Aug; 2(8):807-25. PubMed ID: 7894975
[TBL] [Abstract][Full Text] [Related]
8. Configurations of diastereomeric hydroxyethylene isosteres strongly affect biological activities of a series of specific inhibitors of human-immunodeficiency-virus proteinase.
Konvalinka J; Litera J; Weber J; Vondrásek J; Hradílek M; Soucek M; Pichová I; Majer P; Strop P; Sedlácek J; Heuser AM; Kottler H; Kräusslich HG
Eur J Biochem; 1997 Dec; 250(2):559-66. PubMed ID: 9428710
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.
Ghosh AK; Sean Fyvie W; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
Bioorg Med Chem Lett; 2017 Nov; 27(21):4925-4931. PubMed ID: 28958624
[TBL] [Abstract][Full Text] [Related]
10. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.
Lindberg J; Pyring D; Löwgren S; Rosenquist A; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Classon B; Hallberg A; Samuelsson B; Unge T
Eur J Biochem; 2004 Nov; 271(22):4594-602. PubMed ID: 15560801
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres.
Reddy GS; Ali A; Nalam MN; Anjum SG; Cao H; Nathans RS; Schiffer CA; Rana TM
J Med Chem; 2007 Sep; 50(18):4316-28. PubMed ID: 17696512
[TBL] [Abstract][Full Text] [Related]
12. HIV protease (HIV PR) inhibitor structure-activity-selectivity, and active site molecular modeling of high affinity Leu [CH(OH)CH2]Val modified viral and nonviral substrate analogs.
Sawyer TK; Staples DJ; Liu L; Tomasselli AG; Hui JO; O'Connell K; Schostarez H; Hester JB; Moon J; Howe WJ
Int J Pept Protein Res; 1992; 40(3-4):274-81. PubMed ID: 1478785
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling.
Thanki N; Rao JK; Foundling SI; Howe WJ; Moon JB; Hui JO; Tomasselli AG; Heinrikson RL; Thaisrivongs S; Wlodawer A
Protein Sci; 1992 Aug; 1(8):1061-72. PubMed ID: 1304383
[TBL] [Abstract][Full Text] [Related]
14. Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates.
Weber IT; Wu J; Adomat J; Harrison RW; Kimmel AR; Wondrak EM; Louis JM
Eur J Biochem; 1997 Oct; 249(2):523-30. PubMed ID: 9370363
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 protease inhibitors: ketomethylene isosteres with unusually high affinity compared with hydroxyethylene isostere analogs.
Marinier A; Toth MV; Houseman K; Mueller R; Marshall GR
Bioorg Med Chem; 1994 Sep; 2(9):919-25. PubMed ID: 7712127
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 Protease Uses Bi-Specific S2/S2' Subsites to Optimize Cleavage of Two Classes of Target Sites.
Potempa M; Lee SK; Kurt Yilmaz N; Nalivaika EA; Rogers A; Spielvogel E; Carter CW; Schiffer CA; Swanstrom R
J Mol Biol; 2018 Dec; 430(24):5182-5195. PubMed ID: 30414407
[TBL] [Abstract][Full Text] [Related]
17. Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2' groups.
Rodgers JD; Johnson BL; Wang H; Erickson-Viitanen S; Klabe RM; Bacheler L; Cordova BC; Chang CH
Bioorg Med Chem Lett; 1998 Apr; 8(7):715-20. PubMed ID: 9871528
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays.
Dreyer GB; Lambert DM; Meek TD; Carr TJ; Tomaszek TA; Fernandez AV; Bartus H; Cacciavillani E; Hassell AM; Minnich M
Biochemistry; 1992 Jul; 31(29):6646-59. PubMed ID: 1637805
[TBL] [Abstract][Full Text] [Related]
19. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine.
Baldwin ET; Bhat TN; Gulnik S; Liu B; Topol IA; Kiso Y; Mimoto T; Mitsuya H; Erickson JW
Structure; 1995 Jun; 3(6):581-90. PubMed ID: 8590019
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine.
Le VD; Mak CC; Lin YC; Elder JH; Wong CH
Bioorg Med Chem; 2001 May; 9(5):1185-95. PubMed ID: 11377177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]